Caribou Biosciences (CRBU) Non-Current Debt (2020)
Caribou Biosciences (CRBU) posted quarterly Non-Current Debt of $924000.0 for Q4 2020.
Caribou Biosciences (CRBU) Non-Current Debt (2020) Analysis & Trends
Caribou Biosciences (CRBU) has reported Non-Current Debt for 1 consecutive years, with $924000.0 the latest figure, recorded in Q4 2020.
- In Q4 2020, Non-Current Debt changed N/A year-over-year to $924000.0; the TTM figure through Dec 2020 stood at $924000.0 (changed N/A YoY), while the FY2020 annual figure was $924000.0, changed N/A from the prior year.
- Non-Current Debt steadied at $924000.0 in Q4 2020 per CRBU's latest filing.
- Across five years, Non-Current Debt topped out at $924000.0 in Q4 2020 and bottomed at $924000.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.95 Bn | 132.10 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.71 Bn | 78.72 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 65.71 Bn | 60.52 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.45 Bn | 55.31 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 42.24 Bn | 37.14 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.64 Bn | 10.25 Bn | 668.28 Mn | 360.97 Mn |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - | 8.96 Bn |
| 10 | Caribou Biosciences | 169.15 Mn | 56.84 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 924,000.00 |